BV6
产品说明书
 |
同义名 : | BV-6 free |
| CAS号 : | 1001600-56-1 | |
| 货号 : | A357114 | |
| 分子式 : | C70H96N10O8 | |
| 纯度 : | 99%+ | |
| 分子量 : | 1205.57 | |
| MDL号 : | MFCD28168021 | |
| 存储条件： |
Pure form Keep in dark place, inert atmosphere, store in freezer, under -20°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 55 mg/mL(45.62 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
| 生物活性 | |||
|---|---|---|---|
| 描述 | BV6 is an IAP antagonist with Kd values of o.46nM and 1.3nM for c-IAP and XIAP, respectively. Treatment with BV-6 could cause time (5μM, 2-60min)-dependent c-IAP1 and c-IAP2 ubiquitin degradation in MDA-MB-231 cells. The loss of XIAP can be observed at 8h post treatment. BV-6 led induced caspase-dependent cell death in EVSAT and A2058 cells at concentration ranging in 8-1000nM for 24h concentration-dependently, as well as cell death in MDA-MB-231 at concentration<20nM. And this cell death by BV-6 was TNF dependent. BV-6 at 5μM induced a 15- to 30-fold increase in TNFα mRNA levels and further activated its downstream, both of canonical and noncanonical NF-κB pathways, as the phosphorylation and subsequent proteasomal degradation of IκB, time-dependent increased p52 and p100 and inhibited destabilization of NIK by BV-6 can be observed[1]. After treatment with 10mg/kg BV6, i.p., for 4 weeks could significantly reduce the total number of lesions, the average weight and the surface area of lesions in endometriosis-like model[2]. | ||
| 作用机制 | BV-6 can bind to the BIR domains of IAP proteins and then lead to rapid ubiquitination and proteasomal degradation of cIAPs.[1] | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
0.83mL 0.17mL 0.08mL |
4.15mL 0.83mL 0.41mL |
8.29mL 1.66mL 0.83mL |
